Click on headlines below to download research

The de novo beat
Acarix | 03/01/2020

Acarix has announced that the FDA is reviewing a de novo 510(k) application for its innovative CADScor cardiac diagnostic device. This is important news…

Rights funding completed
Acarix | 06/11/2019

Acarix has competed a rights issue of 28.67m shares at SEK1.50/share to raise SEK43m before expenses. The proceeds will fund a programme of market development…

Patch reordering and an emerging US strategy
Acarix | 27/08/2019

CADScor H1 unit sales were to Germany (six), Sweden (three) and Denmark (one). Interestingly, Q219 patch sales were very strong at 1,690 up from 640 in…

Strong medical support
Acarix | 22/05/2019

Acarix has gained strong support from clinical users, one comments that CADScor will ‘shorten waiting lists and add value for both patients and healthcare…

Favourable market dynamics
Acarix | 14/03/2019

The CADScor medical device helps doctors rule out coronary artery disease and so avoids complex and costly further testing in 50% of cases. Acarix is in…

Favourable market dynamics
Acarix | 14/03/2019

The CADScor medical device helps doctors rule out coronary artery disease and so avoids complex and costly further testing in 50% of cases. Acarix is in…

Sales volume growth in Q3
Acarix | 28/11/2018

Acarix’s Q3 results showed a marked upturn in the number of systems sold: seven in Q3 vs eight in H1. Disposable patch sales in Q3 were 680 vs 800…

Sales consistent in H1
Acarix | 17/09/2018

Acarix’s H1 results show steady sales with eight systems and 800 disposable patches sold to June. These generated H1 revenues of SEK465k with gross…

Sales steady in Q1
Acarix | 30/05/2018

Acarix’s Q1 update shows sales of four systems to March. Revenues were SEK230k with gross profit of SEK158k; a gross margin of 69%. We do not expect…

Updated financial position
Acarix | 08/05/2018

Acarix’s annual report confirms reported 2017 revenues of SEK638k. Gross profit was SEK430k, with a gross margin rise to 75% in Q4. We do not expect…